Objective: Shufeng Jiedu capsule (SFJDC) is a well-known Chinese patent drug that is
recommended as a basic prescription and applied widely in the clinical treatment of COVID-19.
However, the exact molecular mechanism of SFJDC remains unclear. The present study aims to
determine the potential pharmacological mechanisms of SFJDC in the treatment of COVID-19
based on network pharmacology.
Methods: The network pharmacology-based strategy includes collection and analysis of active
compounds and target genes, network construction, identification of key compounds and hub
target genes, KEGG and GO enrichment, recognition and analysis of main modules, as well as
Results: A total of 214 active chemical compounds and 339 target genes of SFJDC were
collected. Of note, 5 key compounds (β -sitosterol, luteolin, kaempferol, quercetin, and
stigmasterol) and 10 hub target genes (TP53, AKT1, NCOA1, EGFR, PRKCA, ANXA1,
CTNNB1, NCOA2, RELA and FOS) were identified based on network analysis. The hub target
genes mainly enriched in pathways including MAPK signaling pathway, PI3K-Akt signaling
pathway and cAMP signaling pathway, which could be the underlying pharmacological
mechanisms of SFJDC for treating COVID-19. Moreover, the key compounds had high binding
activity with three typical target proteins including ACE2, 2OFZ, and 1SSK.
Conclusion: By network pharmacology analysis, SFJDC was found to effectively improve
immune function and reduce inflammatory responses based on its key compounds, hub target
genes, and the relevant pathways. These findings may provide valuable evidence for explaining
how SFJDC exerting the therapeutic effects on COVID-19, providing a holistic view for further